Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -35.66% | 64.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -35.66% | 64.02% | |||
| Cost of Revenue | -5.05% | 23.44% | |||
| Gross Profit | -58.59% | 117.63% | |||
| SG&A Expenses | 117.67% | -35.68% | |||
| Depreciation & Amortization | 0.00% | 0.62% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.12% | 2.42% | |||
| Operating Income | -125.89% | 17,360.00% | |||
| Income Before Tax | -188.02% | 442.86% | |||
| Income Tax Expenses | -39.06% | 233.33% | |||
| Earnings from Continuing Operations | -206.64% | 526.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -206.64% | 526.67% | |||
| EBIT | -125.89% | 17,360.00% | |||
| EBITDA | -100.09% | 369.36% | |||
| EPS Basic | -208.27% | 534.69% | |||
| Normalized Basic EPS | -167.38% | 489.34% | |||
| EPS Diluted | -214.51% | 511.02% | |||
| Normalized Diluted EPS | -171.57% | 466.57% | |||
| Average Basic Shares Outstanding | -1.50% | -1.85% | |||
| Average Diluted Shares Outstanding | -7.26% | 4.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||